Faculty

Scott Luetgenau

MSW, LCAS, CSI
Founder and Principal Consultant
Gatespring

Scott Luetgenau, MSW, LCAS, CSI, is a licensed clinical addiction specialist and the founder of Gatespring, a national behavioral health consulting practice. He trains clinicians on cannabis, nicotine, and emerging drug trends. His recent cannabis sessions include "Clearing the Haze: Vaping, Nicotine, and Cannabis Among Clients Treated for Opioids and/or Stimulants" at the 2026 East Coast Symposium on Addictive Disorders, a cannabis and nicotine session for the Kentucky Society of Addiction Medicine, and a recurring Opioid Response Network training on adolescent tobacco, vaping, and cannabis use, co-occurring disorders, and evidence-based care. His clinical background includes treating co-occurring mental health and substance use disorders as lead therapist of an intensive outpatient program and directing the largest single-site opioid treatment program in North Carolina, which he grew to more than 600 patients. Since 2019 he has delivered more than 150 trainings and technical assistance sessions across 16 states for SAMHSA's Opioid Response Network and the Addiction Technology Transfer Center network, and he has presented at the AATOD National Conference and the Rx and Illicit Drug Summit. He holds a Master of Social Work from the University of North Carolina at Chapel Hill and builds evidence-based, APA-cited curricula for clinical audiences.

2027 Sessions

Engaging for Change: Using Motivational Interviewing to Strengthen Connection

Session Description: Many people enter addiction treatment with mixed feelings about change, external pressure to attend, or uncertainty about the role of services and medications. This interactive session focuses on using core Motivational Interviewing (MI) skills to engage ambivalent clients and support continued connection to care. Participants will briefly review MI spirit and key skills, then apply them to common situations where attendance, follow-through, and participation are at risk.

The session emphasizes recognizing and responding to sustain talk and discord, strengthening the working alliance, and integrating brief MI-consistent strategies into routine contacts (intakes, check-ins, medication conversations, and follow-up visits). Participants will practice adaptable tools such as reflection and affirmation strategies, eliciting change talk with targeted prompts, and a brief “next-step” planning approach that fits real-world time constraints. A brief case example will illustrate how a clinician can respond when a client is mandated, unsure about medication, or minimizes use—without escalating resistance.

By the end of the session, attendees will be prepared to use MI-consistent language and micro-skills to support engagement, reduce discord, and create clearer next steps that help clients stay connected to care.



Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Presenter

Friday, June 04 2:00–3:30 PM
Room Flores 1&2
Faculty

Scott Luetgenau

MSW, LCAS, CSI
Founder and Principal Consultant
Gatespring

Scott Luetgenau, MSW, LCAS, CSI, is a licensed clinical addiction specialist and the founder of Gatespring, a national behavioral health consulting practice. He trains clinicians on cannabis, nicotine, and emerging drug trends. His recent cannabis sessions include "Clearing the Haze: Vaping, Nicotine, and Cannabis Among Clients Treated for Opioids and/or Stimulants" at the 2026 East Coast Symposium on Addictive Disorders, a cannabis and nicotine session for the Kentucky Society of Addiction Medicine, and a recurring Opioid Response Network training on adolescent tobacco, vaping, and cannabis use, co-occurring disorders, and evidence-based care. His clinical background includes treating co-occurring mental health and substance use disorders as lead therapist of an intensive outpatient program and directing the largest single-site opioid treatment program in North Carolina, which he grew to more than 600 patients. Since 2019 he has delivered more than 150 trainings and technical assistance sessions across 16 states for SAMHSA's Opioid Response Network and the Addiction Technology Transfer Center network, and he has presented at the AATOD National Conference and the Rx and Illicit Drug Summit. He holds a Master of Social Work from the University of North Carolina at Chapel Hill and builds evidence-based, APA-cited curricula for clinical audiences.

Cannabis Use Disorder in a High-Potency Era: Practical Assessment and Treatment Across Populations

Session Description: Cannabis use disorder is the most common drug use disorder in the United States: in 2024, 20.6 million people aged 12 and older, or 7.1 percent, met criteria (SAMHSA, 2025). Clinicians across settings see it routinely, often alongside another substance or a mental health condition, yet many were trained when products were far weaker than what clients use today. This session gives experienced clinicians a current, practical approach. It opens with what today's flower, concentrates, vapes, edibles, and hemp-derived products deliver, and why dose and daily use predict risk better than product type. It then works through the presentations most often missed or misread: withdrawal mistaken for an anxiety disorder, cannabinoid hyperemesis syndrome, cannabis-associated psychosis, and the bidirectional links with depression, anxiety, and sleep. The final third focuses on treatment: the approaches with the strongest evidence, including motivational enhancement, cognitive behavioral therapy, and contingency management, and the adjustments that matter for adolescents and young adults, pregnant and parenting clients, older adults, clients with serious mental illness, and clients receiving medication for opioid use disorder. The session closes with what research does and does not support about therapeutic use, so clinicians can respond credibly when clients describe cannabis as medicine. Participants leave with a five-question product history for intake, a withdrawal plan for the first two weeks of reduced use, a three-question screen for cannabinoid hyperemesis syndrome, and goal-setting language for clients who want to cut back rather than stop.

Presenter

Saturday, June 05 3:15–4:45 PM
Faculty

Scott Luetgenau

MSW, LCAS, CSI
Founder and Principal Consultant
Gatespring

Scott Luetgenau, MSW, LCAS, CSI, is a licensed clinical addiction specialist and the founder of Gatespring, a national behavioral health consulting practice. He trains clinicians on cannabis, nicotine, and emerging drug trends. His recent cannabis sessions include "Clearing the Haze: Vaping, Nicotine, and Cannabis Among Clients Treated for Opioids and/or Stimulants" at the 2026 East Coast Symposium on Addictive Disorders, a cannabis and nicotine session for the Kentucky Society of Addiction Medicine, and a recurring Opioid Response Network training on adolescent tobacco, vaping, and cannabis use, co-occurring disorders, and evidence-based care. His clinical background includes treating co-occurring mental health and substance use disorders as lead therapist of an intensive outpatient program and directing the largest single-site opioid treatment program in North Carolina, which he grew to more than 600 patients. Since 2019 he has delivered more than 150 trainings and technical assistance sessions across 16 states for SAMHSA's Opioid Response Network and the Addiction Technology Transfer Center network, and he has presented at the AATOD National Conference and the Rx and Illicit Drug Summit. He holds a Master of Social Work from the University of North Carolina at Chapel Hill and builds evidence-based, APA-cited curricula for clinical audiences.

Back to top